Clinical trials: Severe Community-acquired Pneumonia
Pneumonia, Bacterial
Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE
- Trial name
- NCT00540072
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pneumonia
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
The main aim of the study is to describe plasma pharmacokinetics (PK) and pulmonary diffusion of high-dose ceftobiprole (500 mg loading dose followed by 2.5 g under continuous infusion for 24h) for mechanically-ventilated adult…
- Trial name
- PAC CEF (NCT04171674)
- Testing
- Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).
- Where
- 2 sites in France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Severe Acute Respiratory Infection, Community-acquired Pneumonia
mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients
Severe Community-acquired pneumonia (SCAP) is a leading global infectious cause of intensive care unit (ICU) admission (approximately 20%-30%), and the primary reason of mortality and morbidity in immunocompromised patients.
- Conditions
- Severe Acute Respiratory Infection, Community-acquired Pneumonia, Respiratory Tract Infections, Pneumonia
- Trial name
- MATESHIP (NCT05290454)
- Testing
- mNGS-guided treatment
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Qilu Hospital of Shandong University
Severe Community-acquired Pneumonia (sCAP)
Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)
Severe community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes.
- Trial name
- PANDA-SCAP (NCT07152587)
- Testing
- Low dose steroids, Moderate dose steroids, Saline (0.9% NaCl)
- Volunteers
- 1,500 people
- Sponsor
- Qingyuan Zhan
Community Acquired Respiratory Disease Syndrome
Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
The goal of the study is to determine whether providing early treatment with a glucocorticoid drug, called methylprednisolone, will improve survival in critically ill patients with severe community-acquired pneumonia (CAP).
- Trial name
- ESCAPe (NCT01283009)
- Testing
- Inactive Substance, Methylprednisolone
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 584 people
- Sponsor
- VA Office of Research and Development
Community-acquired Pneumonia
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus placebo, both on top of standard of care, in patients with severe community acquired pneumonia admitted to ICU (or similar unit).
- Trial name
- NCT05962606
- Testing
- AON-D21
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 150 people
- Sponsor
- Aptarion Biotech AG
Community-acquired Pneumonia
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
To assess the effectiveness of a management strategy combining a broad panel respiratory mPCR and an algorithm of early antibiotic de-escalation and discontinuation based on both the mPCR results and the procalcitonin…
- Trial name
- MULTI-CAP (NCT03452826)
- Testing
- Antibiotic therapy according to the result of mPCR (device)
- Where
- France
- Volunteers
- 411 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Community Acquired Pneumonia., Acute Hypoxemic Respiratory Failure
Efects of Noninvasive Mechanical Ventilation and Conventional Mechanical Ventilation in Patients With Severe Comunity Pneumonia
The purpose of this study is to determine whether the noninvasive ventilation is more effective in the treatment of severe comunity acquired pneumonia in comparison with the conventional mechanical ventilation with orotracheal…
- Trial name
- NIMV AND SCAP (NCT00523497)
- Testing
- Non invasive mechanical ventilation
- Where
- Argentina
- Sponsor
- Hospital Privado del Sur
Community-Acquired Pneumonia
Corticoids in Severe Community-Acquired Pneumonia (CAP)
The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V).
- Trial name
- NCT00908713
- Testing
- methylprednisolone
- Where
- 3 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Hospital Clinic of Barcelona
Community-acquired Pneumonia (CAP)
Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.
This study aims to evaluate wether high-dose penicillin V is as effective as high-dose amoxicillin for the treatment of non-sever community-acquired pneumonia (CAP).
- Trial name
- PENIPNEUMO (NCT03208361)
- Testing
- Penicillin V, Amoxicillin
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Intensive Care Unit Syndrome, Community-acquired Pneumonia
Pharmacokinetics of Levofloxacin in Intensive Care Unit
The aim of this study is 1. to describe levofloxacin pharmacokinetics in ICU patients suffering from pneumonia with taking into account physio-pathological parameters. 2.
- Trial name
- LEVO-PHARM (NCT02018081)
- Testing
- Levofloxacin
- Where
- France
- Volunteers
- 52 people
- Sponsor
- University Hospital, Toulouse
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Pneumonia
P4 Peptide in Community Acquired Pneumonia
The investigators' aim is to find out whether immune cells from patients with a severe chest infection will react ex vivo to a new immunomodulating peptide, P4 as part of augmented passive immunotherapy The investigators know…
- Trial name
- P4 (NCT03497962)
- Testing
- Venepuncture, Bronchoscopy
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Community Acquired Pneumonia, Severe
Ticagrelor in Severe Community Acquired Pneumonia
The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia.
- Trial name
- TCAP (NCT01998399)
- Testing
- Ticagrelor
- Where
- 26 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gordon Bernard
Community-Acquired Infections
Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe Pneumonia
This study evaluates the integrated traditional Chinese and Western medicine in the treatment of severe community acquired pneumonia in adults.
- Trial name
- NCT03185923
- Testing
- TCM plus conventional drug
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Severe Community-acquired Pneumonia
Diagnosis and Treatment Strategy Optimization of Severe Pneumonia Based on Multi-omics Data Integration
Severe community-acquired pneumonia still has a high incidence and mortality, but the molecular mechanism and prognostic biomarkers of severe community-acquired pneumonia caused by different pathogens are still unclear, and the…
- Trial name
- NCT06288074
- Testing
- Multi-omics tests
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Sepsis, Severe Community-acquired Pneumonia (sCAP)
Molecular Biomarkers for Sepsis
This multi-center observational case-control study in Intensive Care Unit (ICU) patients is to identify novel biomarkers allowing to recognize severe community acquired pneumonia (sCAP) -associated sepsis at an earlier stage and…
- Conditions
- Sepsis, Severe Community-acquired Pneumonia (sCAP), Infection, Bacterial
- Trial name
- NCT04280354
- Testing
- compare data patterns by data-driven algorithms to determine sepsis, compare data patterns by data-driven algorithms to predict sepsis-related mortality
- Where
- 15 sites in Switzerland
- Volunteers
- 3 people
- Sponsor
- University Hospital, Basel, Switzerland
Community-acquired Pneumonia
MACCE in Hospitalized Patients With Community-acquired Pneumonia
Community-acquired pneumonia is the most common infection leading to hospitalization in intensive care units and the most common cause of death associated with infection disease.
- Trial name
- NCT01773863
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University of Roma La Sapienza
Bacterial Pneumonia
Cx611-0204 SEPCELL Study
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in…
- Trial name
- SEPCELL (NCT03158727)
- Testing
- Cx611
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 84 people
- Sponsor
- Tigenix S.A.U.
Infectious Disease of Lung, Molecular Diagnosis
Clinical Impact of a Multiplex Rapid Diagnostic Pneumonia Panel Testing in Critically-ill Patients With Severe Hospital-acquired Pneumonia, Ventilator-associated Pneumonia and Community-acquired Pneumonia With High Risk of Multidrug Resistant Pathogen
The objective of the research is to ascertain the influence of a syndromic mutiplex PCR assay (FilmArray) on the management of patients hospitalised in the ICU for severe respiratory disease.
- Conditions
- Infectious Disease of Lung, Molecular Diagnosis, Pneumonia
- Trial name
- NCT06782607
- Testing
- Pneumonia Panel by FilmArray
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Mahidol University